Boston Scientific Corporation $BSX Shares Purchased by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 0.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 496,086 shares of the medical equipment provider’s stock after acquiring an additional 555 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Boston Scientific were worth $53,285,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. 1248 Management LLC purchased a new position in Boston Scientific in the 1st quarter worth about $26,000. Y.D. More Investments Ltd purchased a new position in Boston Scientific in the 1st quarter worth about $27,000. Sound Income Strategies LLC increased its stake in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares in the last quarter. Princeton Global Asset Management LLC purchased a new position in Boston Scientific in the 2nd quarter worth about $32,000. Finally, Oliver Lagore Vanvalin Investment Group purchased a new position in Boston Scientific in the 2nd quarter worth about $37,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $101.08 on Friday. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The stock has a market capitalization of $149.78 billion, a PE ratio of 54.06, a price-to-earnings-growth ratio of 2.37 and a beta of 0.61. The stock has a 50 day moving average price of $101.14 and a 200 day moving average price of $102.00. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The firm’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period last year, the firm posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 170,214 shares of company stock worth $17,548,337 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on BSX shares. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research report on Friday. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $124.00 price target on shares of Boston Scientific in a research report on Wednesday. Robert W. Baird boosted their price objective on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. UBS Group boosted their price objective on Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.